Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.
about
Secukinumab for rheumatology: development and its potential place in therapyComparative Effectiveness of Biologic Therapy Regimens for Ankylosing Spondylitis: A Systematic Review and a Network Meta-AnalysisTailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapiesUstekinumab for the treatment of Crohn's disease: can it find its niche?Pharmacological treatment of spondyloarthritis: exploring the effectiveness of nonsteroidal anti-inflammatory drugs, traditional disease-modifying antirheumatic drugs and biological therapiesWhat makes psoriatic and rheumatoid arthritis so different?Making the next steps in psoriatic arthritis management: current status and future directionsIdentifying a novel locus for psoriatic arthritisProfile of ustekinumab and its potential in patients with moderate-to-severe Crohn's disease.Review: The interleukin-23/interleukin-17 axis in spondyloarthritis pathogenesis: Th17 and beyondAdvances in the treatment of polyarticular juvenile idiopathic arthritisBenzoxazepines Achieve Potent Suppression of IL-17 Release in Human T-Helper 17 (TH 17) Cells through an Induced-Fit Binding Mode to the Nuclear Receptor RORγUstekinumab in treatment of Crohn's disease: design, development, and potential place in therapyNew targets in psoriatic arthritisOptimal management of dactylitis in patients with psoriatic arthritisThe Changing Face of Clinical Trials in Psoriatic Arthritis.The Clinical and Cost Effectiveness of Ustekinumab for the Treatment of Psoriatic Arthritis: A Critique of the Evidence.Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders.Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, plaTreatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phasPatient considerations and targeted therapies in the management of psoriasis in Chinese patients: role of ustekinumab.Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted BiologicsUstekinumab for the treatment of psoriatic arthritis: an updateUpdates on Psoriasis and Cutaneous Oncology: Proceedings from the 2014 MauiDerm MeetingDivergent gene activation in peripheral blood and tissues of patients with rheumatoid arthritis, psoriatic arthritis and psoriasis following infliximab therapy.Use of biologic agents in combination with other therapies for the treatment of psoriasisDifferentiation between osteoarthritis and psoriatic arthritis: implications for pathogenesis and treatment in the biologic therapy eraThe Th17 axis in psoriatic disease: pathogenetic and therapeutic implications.Advances and challenges in immunotherapy for solid organ and hematopoietic stem cell transplantationPatient Preferences for Treatment of Psoriasis with Biologicals: A Discrete Choice Experiment.Management of Musculoskeletal Manifestations in Inflammatory Bowel DiseasePatient Preferences for Biologicals in Psoriasis: Top Priority of Safety for Cardiovascular Patients.Serum IL-6 and IL-23 Levels and Their Correlation with Angiogenic Cytokines and Disease Activity in Ankylosing Spondylitis, Psoriatic Arthritis, and SAPHO Syndrome.CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responsesIntegrating longitudinal serum IL-17 and IL-23 follow-up, along with autoantibodies variation, contributes to predict bullous pemphigoid outcomeTofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitorsA novel human truncated IL12rβ1-Fc fusion protein ameliorates experimental autoimmune encephalomyelitis via specific binding of p40 to inhibit Th1 and Th17 cell differentiation.Ustekinumab in the Treatment of Psoriasis and Psoriatic Arthritis.Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2013 MauiDerm Meeting.
P2860
Q26738523-58C14D75-CA5B-499C-B475-00BC868EF7EEQ26764820-0B240B2D-D102-458C-804C-5626E49E36CCQ26764867-A6D21EE5-9385-473D-A45E-D92F7758200CQ26771890-2D8691B3-CB69-48CF-8F93-92A91D7D05EEQ26777084-93ECAAFC-B2F0-48DA-AAE4-8CA66CE4249AQ26778261-2FABF523-622F-4BDF-92F0-B12C5AF0D66CQ26783506-05AAC421-B5C1-4A22-985E-D35DBC17C176Q26800688-1771DD39-D6B3-4F4F-9DBA-11908FF0B042Q26825174-94872D2D-109D-42EF-999F-2004AF3561E4Q26991709-A5FF2D05-3221-4D7C-AABD-9EAE4710EBAAQ27001017-C0A64AC8-0515-414E-B4EC-3112CB157B0BQ27702597-6E9394ED-FC50-4963-8D34-D524931A3628Q28067631-A9856548-8633-49AD-92B7-6E57962A8D6FQ28069592-17235478-7969-4E64-973C-82C79443B92AQ28072557-4913B0BE-1D4F-4889-986B-B934232D57B1Q30235002-BAA22230-1BA7-491F-9870-342C446B62FAQ30383929-8162A261-7A73-4303-9FAB-4537C0224E61Q30399745-083A3B32-C586-4CFA-BF0F-A5FB9A0C9366Q30760660-F86198FD-B2C2-410C-AA82-23A63FA1FD44Q33659004-31E57446-873F-4699-8E8D-6B48865B48E8Q33659249-9C7642E8-D54D-49F7-830B-91ADEF8D2530Q33800651-C0994352-0AC5-4651-A1D7-8E0E144FB989Q33809045-D9050C37-E006-4FD4-A3CE-0BED4E89AAB2Q34154247-76DC99D9-BF6A-4FBD-84BA-9A33380CA90BQ34377347-3EC8F23C-6B00-414F-83FE-A1A0BBCC2A5EQ34380190-641EB506-EBB8-4DB2-80F5-4B706DA54F3FQ34553755-170A30A2-2F3B-4445-9B2A-57144C3244D3Q34727681-7532914F-B30D-43BA-95C2-6D0A743A433BQ35308947-7CC84060-F1C7-4DE0-A296-592D681B14BAQ35586614-4463BBC7-762E-450C-9313-F53D281550DFQ35658540-506D9D84-92C3-45EF-BC4F-C87830E37925Q35773115-A3B20414-9A03-4FD3-B1B0-EE2FBF1867CEQ35860158-F659879B-6E50-44C6-BC95-C18BD00955DEQ35963238-B328AF52-1D6F-4DFC-9E7F-A736A94763B5Q36008355-419E89C6-3250-45AC-95DE-F66C68CC6F28Q36367126-618EB1AE-E7DD-412C-BEE4-DCE004017179Q36475599-58605575-5223-4445-988F-3E62CD267110Q36557095-B250E8E6-BB9D-43F7-9867-B891E645930DQ36942960-453D8DD0-067D-459C-A37B-3BCD94128D10Q37258726-3CBEF2DC-1E57-4814-8DD4-95CE732ABA9B
P2860
Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Efficacy and safety of ustekin ...... bo-controlled PSUMMIT 1 trial.
@en
Efficacy and safety of ustekin ...... bo-controlled PSUMMIT 1 trial.
@nl
type
label
Efficacy and safety of ustekin ...... bo-controlled PSUMMIT 1 trial.
@en
Efficacy and safety of ustekin ...... bo-controlled PSUMMIT 1 trial.
@nl
prefLabel
Efficacy and safety of ustekin ...... bo-controlled PSUMMIT 1 trial.
@en
Efficacy and safety of ustekin ...... bo-controlled PSUMMIT 1 trial.
@nl
P2093
P921
P1433
P1476
Efficacy and safety of ustekin ...... bo-controlled PSUMMIT 1 trial.
@en
P2093
Alan M Mendelsohn
Alice B Gottlieb
Arthur Kavanaugh
Carrie Brodmerkel
Christopher Ritchlin
Mittie K Doyle
PSUMMIT 1 Study Group
Proton Rahman
Yuhua Wang
P304
P356
10.1016/S0140-6736(13)60594-2
P407
P577
2013-06-13T00:00:00Z